Grew Total Revenue to $67.8 million , an Increase of 85% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 3, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2022 .
Review article and commentary in AnnalsATS reinforce clinical utility of genomic test to improve confidence in IPF diagnosis, in conjunction with HRCT and clinical factors SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated
Findings Provide New Insights into Genomic Underpinnings of Prostate and Bladder Cancers SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 28, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting new data on the genomic underpinnings of prostate and bladder
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 26, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new, expanded data demonstrating the performance of the company’s non-invasive Percepta Nasal Swab test in the evaluation of potentially cancerous lung nodules will be presented at
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2022 after the close of market on Tuesday, May 3, 2022 . Company management will host a conference call and webcast to discuss
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 1, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a presentation at Cowen’s 42 nd Annual Health Care Conference on March 8 th at
Grew Fourth Quarter 2021 Revenue to $67.3 Million , an Increase of 95% Grew 2021 Revenue to $219.5 Million , an Increase of 87% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 28, 2022-- Veracyte, Inc.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 28, 2022-- Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has appointed Annie McGuire as senior vice president and general counsel, effective immediately. Ms. McGuire will oversee all aspects of the company’s
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 22, 2022-- Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has appointed Jonathan Wygant as chief accounting officer, effective immediately. Mr. Wygant will oversee all aspects of the company’s global
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 15, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2021 after the close of market on Monday, February 28, 2022 .
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
